RU-58642

RU-58642, also known as HMR-3686 and PSK-3841, is a nonsteroidal antiandrogen (NSAA). It is a synthetic compound that functions as an androgen receptor antagonist, meaning it blocks the effects of androgens like testosterone and dihydrotestosterone (DHT) in the body.

RU-58642 has been investigated for potential use in treating androgen-dependent conditions, particularly androgenetic alopecia (male pattern baldness) and acne. Its mechanism of action involves competing with androgens for binding to the androgen receptor in target tissues such as the scalp and skin. By blocking androgen binding, it can reduce the stimulation of these tissues by androgens, potentially leading to reduced hair loss and decreased sebum production.

The compound has primarily been studied in preclinical research and early clinical trials. While demonstrating promising results in some studies, particularly in topical applications for hair loss, it has not been approved for widespread clinical use as of 2023. Development may be hindered by factors such as potential side effects, efficacy compared to existing treatments, and the economics of bringing a new drug to market.

Furthermore, RU-58642 is considered an experimental compound, and its safety profile and long-term effects in humans are not fully established. Its use is primarily confined to research settings and is not typically prescribed by healthcare professionals outside of clinical trials. Individuals considering using RU-58642 should be aware of the potential risks and lack of comprehensive data regarding its safety and efficacy. It is crucial to consult with a qualified healthcare provider before considering any experimental treatments.